Radius Health Inc. buy tamam
Start price
30.01.18
/
50%
€35.46
Target price
04.11.21
€21.41
Performance (%)
-47.87%
End price
05.11.21
€18.49
Summary
This prediction ended on 05.11.21 with a price of €18.49. The BUY prediction by tamam for Radius Health Inc. performed very badly with a performance of -47.87%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Radius Health Inc. | - | - | - | - |
| iShares Core DAX® | 2,55 % | 0,56 % | 14,14 % | 49,14 % |
| iShares Nasdaq 100 | 2,74 % | -0,60 % | 30,37 % | 82,05 % |
| iShares Nikkei 225® | 6,58 % | 4,34 % | 49,37 % | 60,62 % |
| iShares S&P 500 | 1,93 % | -0,51 % | 24,26 % | 59,66 % |
Comments by tamam for this prediction
In the thread Radius Health Inc. diskutieren
Radius Health could Advance 50% With Osteoporosis Treatment
Morgan Stanley analyst initiated coverage of the company with an Overweight rating and a $57 price target.
Radius is set to launch Tymlos, a bone builder for women with osteoporosis, but despite Eli Lilly's presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, the analyst said Tymlos' pricing is 40 percent lower than Forteo's — and
convenience could help it grab share.
Radius Health is a Conviction Buy!
Kursziel geändert auf 41,414
Kursziel geändert auf 21,414
In the thread Trading Radius Health Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten